Haier Biomedical showcased innovative biostorage and connected pharmaceutical solutions at ISPE Singapore 2026, highlighting advancements in automated systems.

Haier Biomedical (SHA: 688139) memamerkan berbagai solusi otomatis dan digital yang mendukung proses penting dalam penelitian dan pengembangan (R&D), ...

Haier Biomedical presented its innovative automated biostorage and pharmaceutical solutions at the recent ISPE Singapore 2026 event, enhancing workflow efficiency.

At ISPE Singapore 2026, Haier Biomedical presented advanced automated biostorage solutions, enhancing workflow in pharmaceutical R&D and production.

Cryoport, which provides temperature-controlled supply-chain services and equipment to life-science companies, reported second-quarter revenue of $49.0 million, up 7.7% from a year earlier. Its Life Sciences Services revenue rose 14.8%, providing a recent measure of demand for the infrastructure used to move and store sensitive medical products. BioStorage and BioServices revenue increased 24.8% to $5.6 million. Cryoport also said that, at the end of June, it was supporting 779 clinical trials and 22 commercially approved cell and gene therapies. The figures are available in the company's second-quarter filing with the U.S.

Cryoport, Inc. announces an 8% revenue increase in Q2 2026, driven by significant growth in Life Sciences Services and BioStorage. Supporting 779 clinical trials, the company shows a trajectory towards profitability.

Life Sciences Services revenue rose 15%, while BioStorage/BioServices grew 25%; Paris and Santa Ana launches are expected in Q4 2026.

How US-Iran War Reshapes the Biostorage Service Market Dynamics and What Market Research Reports Offer The escalation of geopolitical tensions, notably the US-Iran conflict, has significantly altered ...

-86°C Ultra-Low Temperature Laboratory Freezer (108L) – NANBEI Under-Counter Cryogenic Storage Solution The shift toward decentralised biobanking and point-of-care storage is driving demand for compact, high-reliability cryogenic equipment that can fit into standard laboratory footprints. The race to secure biological materials—vaccines, clinical trial samples, reagents—does not end at the central repository. It ends in the laboratory freezer, where temperature deviations of a few degrees can compromise months of work.

In a macro environment shaped by geopolitical uncertainty, rising tariffs, and uneven biotech sentiment, Cryoport (NASDAQ: CYRX) is leaning into its strengths:

Cryoport reports record financials for FY 2025, highlighting substantial growth and new innovative partnerships in life sciences. A promising outlook for 2026 ahead.

Cryoport (NASDAQ: CYRX) reported its Q4 and FY 2024 financial results, achieving full-year revenue of $228.4 million, aligned with guidance. The company's Commercial Cell & Gene Therapy revenue grew 20% year-over-year to $26 million in FY 2024.Key highlights include supporting 701 global clinical trials, improved gross margin to 45.8% in Q4 2024 (up from 40.6% in Q4 2023), and BioStorage/BioServices revenue growth of 11% in FY 2024. The company added five new approved therapies in 2024, bringing their total commercial therapy count to 19.Financial results show a net loss of $114.8 million for FY 2024, with negative adjusted EBITDA of $15.1 million. The company maintains a strong cash position of $261.7 million and has provided 2025 revenue guidance of $240-250 million.

CRYOGENE to provide cutting-edge biostorage facilities at Moffitt's Speros FL campus, supporting cell and gene therapy development in rapidly expanding market.